QURE News

uniQure N.V. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your Rights - QURE

QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class Action - Hagens Berman

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.

QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders Have Opportunity to Lead Class Action Lawsuit!

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Informs Shareholders of Class Action Against uniQure N.V. – QURE

QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 Ready to Announce with Confidence?

QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design – Hagens Berman

QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design – Hagens Berman

QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design – Hagens Berman